ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001) Study also met secondary endpoints relating to bone mineral density changes in lumbar ...
Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback